Galmed Pharmaceuticals Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Galmed Pharmaceuticals Ltd. generated cash of -$6,137,000, which is more than the previous year. Cash used in financing activities reached the amount of $6,185,000 last year. Net change in cash is therefore $848,000.
Cash Flow
| 2014 | -9.24M | -9.01M | 41.85M |
|---|---|---|---|
| 2015 | -8.47M | -11.10M | 0 |
| 2016 | -12.12M | 6.33M | 4.73M |
| 2017 | -12.06M | 6.44M | 15.54M |
| 2018 | -9.02M | -60.01M | 80.17M |
| 2019 | -14.93M | 6.67M | 143K |
| 2020 | -26.28M | 16.53M | 768K |
| 2021 | -32.89M | 11.46M | 17.36M |
| 2022 | -18.50M | 17.56M | 70K |
| 2023 | -6.13M | 800K | 6.18M |
GLMD Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.13M | 2.99M | 7.06M | 16.04M | 24.15M | 13.02M | 3.09M | 4.15M | 23.73M | 137K |
Operating activities | ||||||||||
Net income | -6.91M | -17.86M | -32.46M | -28.77M | -20.46M | -9.85M | -12.29M | -16.95M | -10.62M | -9.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 31K | 35K | 42K | 39K | 35K | 387K | 239K | 169K | 50K | 9K |
Stock-based compensation expense | 892K | 1.29M | 1.88M | 2.06M | 2.23M | 0 | 1.39M | 1.62M | 970K | 601K |
| Deferred income tax benefit | 892K | 1.29M | 1.88M | 2.06M | 2.23M | 0 | 1.39M | 1.62M | 970K | 601K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 345K | 300K | -313K | 15K | -609K | -63K | 129K | 95K | -214K | -149K |
Inventories | 0 | -300K | 313K | -15K | 609K | -142K | 671K | 81K | 39K | -91K |
Accounts payable | -681K | -2.31M | -2.17M | 1.04M | 4.18M | -462K | -846K | 863K | 1.38M | -480K |
Cash generated by operating activities | -6.13M | -18.50M | -32.89M | -26.28M | -14.93M | -9.02M | -12.06M | -12.12M | -8.47M | -9.24M |
Investing activities | ||||||||||
Purchases Of Investments | -6.33M | -3.87M | -13.56M | -55.03M | -94.40M | -98.34M | -3.86M | -7.61M | -26.54M | -8.24M |
Investments In Property Plant And Equipment | 0 | -4K | -11K | -44K | -12K | -90K | -21K | -17K | -159K | -770K |
Acquisitions Net | -1.5M | -17.56K | 0 | -24.94M | 21.79M | 6.07M | 0 | 13K | -6M | 8.24M |
Cash generated by investing activities | 800K | 17.56M | 11.46M | 16.53M | 6.67M | -60.01M | 6.44M | 6.33M | -11.10M | -9.01M |
Financing activities | ||||||||||
Common Stock Issued | 6.18M | 70K | 17.36M | 707K | 143K | 0 | 15.01M | 4.47M | 0 | 41.85M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 6.18M | 70K | 17.36M | 768K | 143K | 80.17M | 15.54M | 4.73M | 0 | 41.85M |
Net Change In Cash | 848K | -868K | -4.06M | -8.98M | -8.11M | 11.13M | 9.92M | -1.05M | -19.58M | 23.59M |
Cash at end of period | 2.97M | 2.13M | 2.99M | 7.06M | 16.04M | 24.15M | 13.02M | 3.09M | 4.15M | 23.73M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |